<DOC>
	<DOCNO>NCT02478957</DOCNO>
	<brief_summary>This randomize , placebo- active-controlled , 2-period crossover , 2 cohort study adult patient indolent systemic mastocytosis ( ISM ) . The purpose study determine efficacy safety profile PA101 deliver via eFlow high efficiency nebulizer patient ISM symptomatic despite use standard treatment .</brief_summary>
	<brief_title>Treatment Indolent Systemic Mastocytosis With PA101</brief_title>
	<detailed_description>The symptom score determine eligibility establish 2-week Run-in Period use eDiary eligible patient randomly allocate 2:1 ratio one two treatment cohort baseline visit . In Cohort 1 ( n=24 ) , patient receive inhaled 40 mg PA101 three time daily inhale placebo three time daily via eFlow 6 week double-blind , 2-period crossover fashion 4-week washout period treatment period . In Cohort 2 ( n=12 ) , patient receive inhaled 40 mg PA101 three time daily via eFlow oral cromolyn sodium 200 mg four time daily 6 week open label , 2-period crossover fashion 4-week washout period treatment period . Patients allow use daily dos pre-randomization H1 H2 antihistamine well daily dos allow medication treatment period . Visits treatment period occur baseline Visit , end Weeks 1 , 2 , 4 , 6 . Blood urine sample collect test various biomarkers . In subset patient , additional clinical assessment skin perform blood sample collect pharmacokinetic assessment . Clinical safety assessment perform patient start end treatment period .</detailed_description>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Mastocytosis , Systemic</mesh_term>
	<criteria>Diagnosis indolent systemic mastocytosis ( ISM ) accord WHO criteria consensus proposal ( 2001 ) Experiencing least one predefined qualify symptom least two organ system within 3 month Screening despite use H1 and/or H2 antihistamine antimediator therapy Experiencing symptom severity score least 4 least 7 14 day Runin period least one predefined qualify symptom least two organ system , despite use H1 and/or H2 antihistamines and/or antimediator therapy Willing able use eDiary device daily duration study Completed least 5 eDiary report two consecutive week Runin period Willing able provide write informed consent prior study procedure Advanced systemic mastocytosis ( i.e. , aggressive systemic mastocytosis [ ASM ] , mast cell leukemia [ MCL ] , systemic mastocytosis associate clonal hematologic nonmast cell lineage disease [ SMAHNMD ] ) Current recent history clinically significant cardiovascular , hematological , renal , neurologic , hepatic , endocrine , psychiatric , malignant , illness could put patient risk compromise quality study data determine Investigator Use oral cromolyn sodium within 6 week Screening History systemic corticosteroid , immunosuppressive , antiIgE monoclonal antibody therapy ( e.g. , omalizumab ) within 6 month Screening History anaphylaxis require systemic treatment ( i.e. , corticosteroid epinephrine ) within 12 month Screening Upper low respiratory tract infection within 4 week Screening History malignancy within last 5 year , except basal cell carcinoma cervix carcinoma situ Major surgery within 6 month Screening Current recent history ( within 12 month ) excessive use abuse alcohol Current recent history ( within 12 month ) abuse legal drug use illegal drug substance Pregnant breastfeeding female , childbearing potential unwilling practice acceptable mean birth control abstinence study Participation investigational drug study within 4 week Screening History hypersensitivity intolerance aerosol medication cromolyn sodium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>mastocytosis</keyword>
	<keyword>cromolyn sodium</keyword>
</DOC>